Advanced breast cancer therapy received a boost last week when Novartis Pharmaceuticals Corporation announced that the supplemental new drug application for FemaraÒ
(letrozole tablets), as first-line therapy in postmenopausal women with advanced breast cancer, has been designated for priority review by the U.S. Food and Drug Administration (FDA).
The recommended dose of Femara (letrozole tablets) is one 2.5 mg tablet administered once a
day, without regard to meals. Treatment with Femara should continue until tumor progression is evident. No dose adjustment is required for elderly patients. Patients treated with Femara do not require glucocorticoid or mineralocorticoid replacement therapy. We have the rest of the prescribing information for you in today's issue.
In anesthesia and pain management news, a new report prepared for the federal Agency for Healthcare Research and Quality (AHRQ) concludes that currently employed approaches to anesthesia management provide adequate pain control for successful cataract surgery. But the report also says that more data are needed on patient preferences and cost effectiveness to determine the optimal strategies for anesthesia management during cataract surgery.
Variant Cruetzfeldt-Jakob (vCJD) disease is in the news again. British doctors told the London, Sunday Telegraph that they believe a baby has been born with new variant Creutzfeldt-Jakob disease (vCJD). An 11-month old girl, whose mother died earlier this year, is exhibiting symptoms of the disease. If her illness is confirmed, she will be the first known case of maternal-infant transmission of vCJD.
And finally, oh, oh, oh, Olestra! Frequent consumption of potato chips, tortilla chips or other savory snack foods made with the fat substitute olestra is associated with a significant reduction in serum cholesterol levels and dietary fat intake, according to researchers at the Fred Hutchinson Cancer Research Center in Seattle. The findings are in today's issue and in today's issue of The Archives of Internal Medicine.
The articles in today's Vidyya are:
As always, we hope you enjoy the issue.